Adverse events and complications associated with intravitreal injection of anti-VEGF agents: A review of literature

Eye (Basingstoke)

Volumn 27, Issue 7, 2013, Pages 787-794

  Falavarjani, K Ghasemi ^a   Nguyen, Q D ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Aflibercept; Anti vascular endothelial growth factor; Bevacizumab; Intravitreal injection; Ranibizumab; Safety

Indexed keywords

AFLIBERCEPT; ANTIBIOTIC AGENT; BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; VASCULOTROPIN INHIBITOR;

ABDUCENS NERVE PARALYSIS; ADVERSE DRUG REACTION; ANTERIOR ISCHEMIC OPTIC NEUROPATHY; ASEPSIS; BACTERIUM CONTAMINATION; BLOOD PRESSURE; CEREBROVASCULAR ACCIDENT; DIABETIC RETINOPATHY; DRUG FATALITY; DRUG SAFETY; ECCHYMOSIS; ENDOPHTHALMITIS; EYE DISEASE; EYE INFLAMMATION; GASTROINTESTINAL HEMORRHAGE; GLAUCOMA; HEART INFARCTION; HEMATOMA; HUMAN; ILIAC ARTERY ANEURYSM; INTRAOCULAR HEMORRHAGE; INTRAOCULAR PRESSURE; OCULAR ISCHEMIC SYNDROME; RETINA ARTERY OCCLUSION; RETINA BLOOD VESSEL OCCLUSION; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINA VEIN OCCLUSION; REVIEW; SIDE EFFECT; SUBDURAL HEMATOMA; VAGINA BLEEDING; VITRECTOMY;

EID: 84880268774     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2013.107     Document Type: Review

References (87)

1. Wong TY, Liew G, Mitchell P. Clinical update: new treatments for age-related macular degeneration. Lancet 2007; 370(9583): 204-206.
2. Nicholson BP, Schachat AP. A review of clinical trials of anti-VEGF agents for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2010; 248(7): 915-930.
3. Wong TY, Scott IU. Clinical practice. Retinal-vein occlusion. N Engl J Med 2010; 363(22): 2135-2144.
4. Falavarjani KG, Modarres M, Nazari H. Therapeutic effect of bevacizumab injected into the silicone oil in eyes with neovascular glaucoma after vitrectomy for advanced diabetic retinopathy. Eye 2010; 24: 717-719.
5. Nazari H, Parvaresh MM, Modarres M, Falavarjani KG. Intravitreal bevacizumab in combination with laser therapy for the treatment of severe retinopathy of prematurity (ROP) associated with vitreous or retinal hemorrhage. Graefes Arch Clin Exp Ophthalmol 2010; 248: 1713-1718.
6. Detorakis ET, Agorogiannis G, Drakonaki EE, Tsilimbaris MK, Pallikaris IG. Successful management of choroidal metastasis with intravitreal ranibizumab injection. Ophthalmic Surg Lasers Imaging 2012; 43: e47-e51.
7. Ip MS, Scott IU, Brown GC, Brown MM, Ho AC, Huang SS et al. Antivascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology. Ophthalmology 2008; 115: 1837-1846.
8. Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010; 117: 1102-1112.
9. Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RDE. Ophthalmology 2012; 119: 789-801.
10. McCannel CA. Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. Retina 2011; 31: 654-661.
11. Scott IU, Flynn Jr, HW. Reducing the risk of endophthalmitis following intravitreal injections. Retina 2007; 27: 10-12.
12. Fintak DR, Shah GK, Kj Blinder, Regillo CD, Pollack J, Heier JS et al. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina 2008; 28: 1395-1399.
13. Diago T, McCannel CA, Bakri SJ, Pulido JS, Edwards AO, Pach JM. Infectious endophthalmitis after intravitreal injection of antiangiogenic agents. Retina 2009; 29: 601-605.
14. Mason 3rd, JO, White MF, Feist RM, Thomley ML, Albert MA, Persaud TO et al. Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection. Retina 2008; 28(4): 564-567.
15. Pilli S, Kotsolis A, Spaide RF, Slakter J, Freund KB, Sorenson J et al. Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting. Am J Ophthalmol 2008; 145(5): 879-882.
16. Moshfeghi AA, Rosenfeld PJ, Flynn Jr, HW, Schwartz SG, Davis JL, Murray TG et al. Endophthalmitis after intravitreal anti-vascular endothelial growth antagonists. Retina 2011; 31: 662-668.
17. Falavarjani KG, Modarres M, Hashemi M, Parvaresh MM, Naseripour M, Zare-Moghaddam A et al. Incidence of acute endophthalmitis after intravitreal bevacizumab injection in a single clinical center. Retina 2013; 33(5): 971-974.
18. Goldberg RA, Flynn HW, Isom RF, Miller D, Gonzalez S. An outbreak of streptococcus endophthalmitis after intravitreal injection of bevacizumab. Am J Ophthalmol 2012; 153(2): 204-208.
19. Gonzalez S, Rosenfeld PJ, Stewart MW, Brown J, Murphy SP. Avastin doesn't blind people, people blind people. Am J Ophthalmol 2012; 153(2): 196-203.
20. Yu CQ, Ta CN. Prevention of postcataract endophthalmitis: evidence-based medicine. Curr Opin Ophthalmol 2012; 23(1): 19-25.
21. Doshi RR, Leng T, Fung AE. Reducing oral flora contamination of intravitreal injections with face mask or silence. Retina 2012; 32(3): 473-476.
22. Wen JC, McCannel CA, Mochon AB, Garner OB. Bacterial dispersal associated with speech in the setting of intravitreous injections. Arch Ophthalmol 2011; 129(12): 1551-1554.
23. Green-Simms AE, Ekdawi NS, Bakri SJ. Survey of intravitreal injection techniques among retinal specialists in the United States. Am J Ophthalmol 2011; 151(2): 329-332.
24. Milder E, Vander J, Shah C, Garg S. Changes in antibiotic resistance patterns of conjunctival flora due to repeated use of topical antibiotics after intravitreal injection. Ophthalmology 2012; 119(7): 1420-1424.
25. Tolentino M. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol 2011; 56: 95-113.
26. Mezad-Koursh D, Goldstein M, Heilwail G, Zayit-Soudry S, Loewenstein A, Barak A. Clinical characteristics of endophthalmitis after an injection of intravitreal antivascular endothelial growth factor. Retina 2010; 30: 1051-1057.
27. Shah CP, Garg SJ, Vander JF, Brown GC, Kaiser RS, Haller JA. Post-Injection Endophthalmitis (PIE) Study Team. Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. Ophthalmology 2011; 118: 2028-2034.
28. Irigoyen C, Ziahosseini K, Morphis G, Stappler T, Heimann H. Endophthalmitis following intravitreal injections. Graefes Arch Clin Exp Ophthalmol 2012; 250(4): 499-505.
29. Meyer CH, Michels S, Rodrigues EB, Hager A, Mennel S, Schmidt JC et al. Incidence of rhegmatogenous retinal detachments after intravitreal antivascular endothelial factor injections. Acta Ophthalmol 2011; 89: 70-75.
30. Bakri SJ, Pulido JS, McCannel CA, Hodge DO, Diehl N, Hillemeier J. Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. Eye 2009; 23(1): 181-185.
31. Gismondi M, Salati C, Salvetat ML, Zeppieri M, Brusini P. Short-term effect of intravitreal injection of Ranibizumab (Lucentis) on intraocular pressure. J Glaucoma 2009; 18(9): 658-661.
32. Kahook MY, Kimura AE, Wong LJ, Ammar DA, Maycotte MA, Mandava N. Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections. Ophthalmic Surg Lasers Imaging 2009; 40: 293-295.
33. Hoang QV, Mendonca LS, Della Torre KE, Jung JJ, Tsuang AJ, Freund KB. Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections. Ophthalmology 2012; 119: 321-326.
34. Good TJ, Kimura AE, Mandava N, Kahook MY. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol 2011; 95: 1111-1114.
35. Ladas ID, Karagiannis DA, Rouvas AA, Kotsolis AI, Liotsou A, Vergados I. Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: our experience after 2,000 injections. Retina 2009; 29(3): 313-318.
36. Brouzas D, Koutsandrea C, Moschos M, Papadimitriou S, Ladas I, Apostolopoulos M. Massive choroidal hemorrhage after intravitreal administration of bevacizumab (Avastin) for AMD followed by contralateral sympathetic ophthalmia. Clin Ophthalmol 2009; 3: 457-459.
37. Karagiannis DA, Mitropoulos P, Ladas ID. Large subretinal haemorrhage following change from intravitreal bevacizumab to ranibizumab. Ophthalmologica 2009; 223(4): 279-282.
38. Modarres M, Naseripour M, Falavarjani KG, Nikeghbali A, Hashemi M, Parvaresh MM. Intravitreal injection of 2.5 mg vs 1.25 mg bevacizumab (avastin) for treatment of CNV associated with AMD. Retina 2009; 29: 319-324.
39. Loukopoulos V, Meier C, Gerding H. Hemorrhagic complications after intravitreal injections of ranibizumab in patients under coumarin-type anticoagulation. Klin Monbl Augenheilkd 2010; 227(4): 289-291.
40. Mason 3rd JO, Frederick PA, Neimkin MG, White Jr MF, Feist RM, Thomley ML et al. Incidence of hemorrhagic complications after intravitreal bevacizumab (avastin) or ranibizumab (lucentis) injections on systemically anticoagulated patients. Retina 2010; 30(9): 1386-1389.
41. Gordon MS, Cunningham D. Managing patients treated with bevacizumab combination therapy. Oncology 2005; 69(Suppl 3): 25-33.
42. Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007; 99: 1232-1239.
43. Csaky K, Do DV. Safety implications of vascular endothelial growth factor blockade for subjects receiving intravitreal anti-vascular endothelial growth factor therapies. Am J Ophthalmol 2009; 148: 647-656.
44. Schmidt-Erfurth U. Clinical safety of ranibizumab in agerelated macular degeneration. Expert Opin Drug Saf 2010; 9(1): 149-165.
45. Lim LS, Cheung CG, Mitchell P, Wong TY. Emerging evidence concerning systemic safety of anti-VEGF agents - should ophthalmologists be concerned? Am J Ophthalmol 2011; 152: 329-331.
46. Schmucker C, Loke YK, Ehlken C, Agostini HT, Hansen LL, Antes G et al. Intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a safety review. Br J Ophthalmol 2011; 95(3): 308-317.
47. Schmucker C, Ehlken C, Agostini HT, Antes G, Ruecker G, Lelgemann M et al. A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard. PLoS One 2012; 7(8): e42701.
48. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, Arevalo JF, Berrocal MH, Farah ME et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 2008; 246(1): 81-87.
49. Gower EW, Cassard S, Chu L, Varma R, Klein R. Adverse event rates following intravitreal injection of avastin or lucentis for treating age-related macular degeneration. ARVO Meet Abstr 2011; 52: 6644.
50. van der Reis MI, La Heij EC, De Jong-Hesse Y, Ringens PJ, Hendrikse F, Schouten JS. A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections. Retina 2001; 31: 1449-1469.
51. The Royal College of Ophthalmologists. Statement. Bevacizumab (Avastin) Use in Medical Ophthalmology 2011. Available at : http://www.rcophth.ac.uk/news. asp? itemid=647&itemTitle=RCOphth+Review+concludes+ that+Avastin+and+Lucentis+are+equally+effec tive+in+treating+wet+AMD& section=24§ion Title=News. Accessed 02 April 2012.
52. Ganssauge M, Wilhelm H, Bartz-Schmidt KU, Aisenbrey S. Nonarteritic anterior ischemic optic neuropathy (NA-AION) after intravitreal injection of bevacizumab (Avastin) for treatment of angoid streaks in pseudoxanthoma elasticum. Graefes Arch Clin Exp Ophthalmol 2009; 247(12): 1707-1710.
53. Hosseini H, Razeghinejad MR. Anterior ischemic optic neuropathy after intravitreal injection of bevacizumab. J Neuroophthalmol 2009; 29(2): 160-161.
54. Mansour AM, Bynoe LA, Welch JC, Pesavento R, Mahendradas P, Ziemssen F et al. Retinal vascular events after intravitreal bevacizumab. Acta Ophthalmol 2010; 88(7): 730-735.
55. von Hanno T, Kinge B, Fossen K. Retinal artery occlusion following intravitreal anti-VEGF therapy. Acta Ophthal 2010; 88(2): 263-266.
56. Furino C, Boscia F, Cardascia N, Alessio G, Sborgia C. Hemorrhagic macular infarction after intravitreal bevacizumab for central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2010; e-pub ahead of print 9 March 2010; doi: 10.3928/15428877-20100215-57.
57. Huang ZL, Lin KH, Lee YC, Sheu MM, Tsai RK. Acute vision loss after intravitreal injection of bevacizumab (avastin) associated with ocular ischemic syndrome. Ophthalmologica 2010; 224(2): 86-89.
58. Cakmak HB, Toklu Y, Yorgun MA, Simşek S. Isolated sixth nerve palsy after intravitreal bevacizumab injection. Strabismus 2010; 18(1): 18-20.
59. Meyer CH, Mennel S, Hörle S, Schmidt JC. Visual hallucinations after intravitreal injection of bevacizumab in vascular agerelated macular degeneration. Am J Ophthalmol 2007; 143(1): 169-170.
60. Yohendran J, Chauhan D. Erectile dysfunction following intravitreal bevacizumab. Middle East Afr J Ophthalmol 2010; 17(3): 281-284.
61. Pellé G, Shweke N, Duong Van Huyen JP, Tricot L, Hessaïne S, Frémeaux-Bacchi V et al. Systemic and kidney toxicity of intraocular administration of vascular endothelial growth factor inhibitors. Am J Kidney Dis 2011; 57(5): 756-759.
62. Falavarjani KG, Modarres M. Perioperative use of bevacizumab in vitrectomy for proliferative diabetic retinopathy: a literature review. Iranian J Ophthalmol 2010; 22(4): 5-12.
63. Arevalo JF, Maia M, Flynn Jr HW, Saravia M, Avery RL, Wu L et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 2008; 92(2): 213-216.
64. Oshima Y, Shima C, Wakabayashi T, Kusaka S, Shiraga F, Ohji M et al. Microincision vitrectomy surgery and intravitreal bevacizumab as a surgical adjunct to treat diabetic traction retinal detachment. Ophthalmology 2009; 116(5): 927-938.
65. Yeh PT, Yang CM, Lin YC, Chen MS, Yang CH. Bevacizumab pretreatment in vitrectomy with silicone oil for severe diabetic retinopathy. Retina 2009; 29(6): 768-774.
66. Modarres M, Nazari H, Falavarjani KG, Naseripour M, Hashemi M, Parvaresh MM. Intravitreal injection of bevacizumab before vitrectomy for proliferative diabetic retinopathy. Eur J Ophthalmol 2009; 19(5): 848-852.
67. Arevalo JF, Sanchez JG, Laave AF, Wu L, Maia M, Bonafonte S et al. Intravitreal bevacizumab (avastin) for diabetic retinopathy: The 2010 GLADAOF lecture. J Ophthalmol 2011; 2011: 584238.
68. Liu L, Wu WC, Yeung L, Wang NK, Kuo YH, Chao AN et al. Ghost cell glaucoma after intravitreal bevacizumab for postoperative vitreous hemorrhage following vitrectomy for proliferative diabetic retinopathy. Ophthalmic Surg Lasers Imaging 2010; 41(1): 72-77.
69. Mete A, Saygili O, Mete A, BayramM, Bekir N. Effects of intravitreal bevacizumab (Avastin) therapy on retrobulbar blood flow parameters in patients with neovascular age-related macular degeneration. J Clin Ultrasound 2010; 38(2): 66-70.
70. Papadopoulou DN, Mendrinos E, Mangioris G, Donati G, Pournaras CJ. Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration. Ophthalmology 2009; 116(9): 1755-1761.
71. Manousaridis K, Talks J. Macular ischemia: a contraindication for anti-VEGF treatment in retinal vascular disease? Br J Ophthalmol 2012; 96: 179-184.
72. Chang LK, Flaxel CJ, Lauer AK, Sarraf D. RPE tears after pegaptanib treatment in age-related macular degeneration. Retina 2007; 27: 857-863.
73. Smith BT, Kraus CL, Apte RS. Retinal pigment epithelial tears in ranibizumab-treated eyes. Retina 2009; 29: 335-339.
74. Shaikh S, Olson JC, Richmond PP. Retinal pigment epithelial tears after intravitreal bevacizumab injection for exudative age-related macular degeneration. Indian J Ophthalmol 2007; 55: 470-472.
75. Chang LK, Sarraf D. Tears of the retinal pigment epithelium: an old problem in a new era. Retina 2007; 27(5): 523-534.
76. Chiang A, Chang LK, Yu F, Sarraf D. Predictors of anti-VEGF-associated retinal pigment epithelial tear using FA and OCT analysis. Retina 2008; 28(9): 1265-1269.
77. Cunningham Jr, ET, Feiner L, Chung C, Tuomi L, Ehrlich JS. Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age-related macular degeneration. Ophthalmology 2011; 118(12): 2447-2452.
78. Quiroz-Mercado H, Martinez-Castellanos MA, Hernandez- Rojas ML, Salazar-Teran N, Chan RV. Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity. Retina 2008; 28(Suppl): S19-S25.
79. Honda S, Hirabayashi H, Tsukahara Y, Negi A. Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 2008; 246: 1061-1063.
80. Wu WC, Yeh PT, Chen SN, Yang CM, Lai CC, Kuo HK. Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in Taiwan. Ophthalmology 2011; 118: 176-183.
81. Lee BJ, Kim JH, Heo H, Yu YS. Delayed onset atypical vitreoretinal traction band formation after an intravitreal injection of bevacizumab in stage 3 retinopathy of prematurity. Eye (Lond) 2012; 26: 903-910.
82. Hu J, Blair MP, Shapiro MJ, Lichtenstein SJ, Galasso JM, Kapur R. Reactivation of retinopathy of prematurity after bevacizumab injection. Arch Ophthalmol 2012; 130(8): 1000-1006.
83. Goel N, Kumar V, Seth A, Raina UK, Ghosh B. Role of intravitreal bevacizumab in adult onset Coats disease. Int Ophthalmol 2011; 31: 183-190.
84. Bohm MR, Uhlig CE. Use of intravitreal triamcinolone and bevacizumab in Coats' disease with central macular edema. Graefes Arch Clin Exp Ophthalmol 2011; 249: 1099-1101.
85. Ramasubramanian A, Shields CL. Bevacizumab for Coats' disease with exudative retinal detachment and risk of vitreoretinal traction. Br J Ophthalmol 2012; 96: 356-359.
86. Higashide T, Murotani E, Saito Y, Ohkubo S, Sugiyama K. Adverse events associated with intraocular injections of bevacizumab in eyes with neovascular glaucoma. Graefes Arch Clin Exp Ophthalmol 2012; 250(4): 603-610.
87. Kumar A, Sehra SV, Thirumalesh MB, Gogia V. Secondary rhegmatogenous retinal detachment following intravitreal bevacizumab in patients with vitreous hemorrhage or tractional retinal detachment secondary to Eales' disease. Graefes Arch Clin Exp Ophthalmol 2012; 250: 685-690.